Published financial brief
0115B
NYMOX PHARMACEUTICAL CORP
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
4 data notes
- Input provenance requires review.
- A ratio denominator is near zero.
- One or more values are unavailable.
- A displayed ratio exceeds the warning bound.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 0 | 0 | 0 | 0 | 0 |
| Cost of goods soldUSD millions | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenseUSD millions | 11.7 | 12.5 | 6.6 | 8.3 | 4.3 |
| Depreciation and amortizationUSD millions | 0 | 0 | 0 | 0 | 0 |
| Net incomeUSD millions | -11.7 | -12.5 | -6.6 | -8.8 | -4.5 |
| Operating profit (EBIT)USD millions | -11.7 | -12.5 | -6.7 | -8.4 | -4.3 |
| Income taxesUSD millions | 0 | 0 | 0 | 0 | 0 |
| Short-term debtUSD millions | 0.1 | 0.2 | 0.2 | 0.8 | 3.3 |
| Long-term debtUSD millions | 0.4 | 0.2 | 0 | 0 | 0 |
| Cash and equivalentsUSD millions | 3.6 | 0.8 | 1.4 | 0.1 | 0.1 |
| ReceivablesUSD millions | 0 | 0 | 0 | 0 | 0 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 1.4 | 1.3 | 1.7 | 3 | 4.1 |
| Net property, plant and equipmentUSD millions | 0.5 | 0.4 | 0.2 | 0 | 0 |
| Capital expenditureUSD millions | 0 | 0 | 0 | 0 | 0 |
| Operating cash flowUSD millions | -10 | -9.8 | -5.2 | -4.1 | -2.6 |
| Prepaid expensesUSD millions | —missing | —missing | —missing | 0 | 0 |
| AccrualsUSD millions | 0.3 | 0.3 | 0.2 | 0 | 0 |
| EBITDAUSD millions | -11.7 | -12.5 | -6.6 | -8.3 | -4.3 |
| Working capitalUSD millions | 2.1 | -0.7 | -0.7 | -3.2 | -6.8 |
| Working capital requirementUSD millions | -1.3 | -1.2 | -1.7 | -3 | -4.1 |
| Total debtUSD millions | 0.4 | 0.4 | 0.2 | 0.8 | 3.3 |
| Free cash flowUSD millions | -10.1 | -9.8 | -5.2 | -4.1 | -2.6 |
| Unlevered free cash flowUSD millions | -12 | -12.6 | -6.2 | -7 | -3.2 |
| Returns and ratios | |||||
| ROICratio | 1,303.7% | 1,524.9% | 437.9% | 277.4% | 104.8% |
| Pre-tax ROICratio | 1,303.7% | 1,524.9% | 437.9% | 277.4% | 104.8% |
| Effective tax rateratio | 0% | 0% | 0% | 0% | 0% |
| Revenue growthratio | -95.7% | -100% | —missing | —missing | —missing |
| EBIT / Revenueratio | -234,400% | —missing | —missing | —missing | —missing |
| Revenue / Invested capitalmultiple | -0.01× | 0× | 0× | 0× | 0× |
| Cogs Over Revenuesratio | 80% | —missing | —missing | —missing | —missing |
| Sga Over Revenuesratio | 234,240% | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | 180% | —missing | —missing | —missing | —missing |
| Nfa Over Revenuesratio | 9,000% | —missing | —missing | —missing | —missing |
| Wcr Over Revenuesratio | -26,980% | —missing | —missing | —missing | —missing |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0.02× | 0.27× | 0.12× | 10.71× | 44.41× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | -0× | -0× | -0.01× | -0.02× | -0.09× |
| Nsf Over Wcrmultiple | 2.63× | 0.49× | 0.73× | -0.23× | -0.79× |
Ask this snapshot
Research assistant
0115B · annualSnapshot c26356d1
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000